Abstract
The management of pancreatic cancer has grown rapidly in the last decade. The Gastrointestinal Tumor Study Group trial in 1985 supported postoperative chemoradiation, and a more recent study recommended 6 months of adjuvant gemcitabine and capecitabine or monotherapy with gemcitabine or fluorouracil plus folinic acid, in the absence of neoadjuvant therapy. Clinicians are now studying the role of targeted therapy in pancreatic cancer and neoadjuvant chemotherapy in resectable, borderline resectable, and locally advanced pancreatic cancer. This article critically evaluates the evolution of pancreatic cancer management, focussing on level 1a, prospective randomized control trials from 2007 to 2017.
| Original language | English |
|---|---|
| Pages (from-to) | 767-790 |
| Number of pages | 24 |
| Journal | Surgical Oncology Clinics of North America |
| Volume | 26 |
| Issue number | 4 |
| DOIs | |
| State | Published - Oct 2017 |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Keywords
- Chemoradiation
- Chemotherapy
- Pancreatic cancer
- Randomized control trails
- Randomized trials
Fingerprint
Dive into the research topics of 'Randomized Clinical Trials in Pancreatic Cancer'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver